



CareDx Completes Expansion of CLIA Laboratory with Next-Generation Sequencing Platform Capability

Purpose-Built Facility Dedicated to Testing Donor-Derived Cell-Free DNA (dd-cfDNA)

BRISBANE, Calif. November 2, 2015: CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant recipients, announced the expansion to their CLIA lab specifically designed for clinical-grade next-generation sequencing (NGS) testing in Brisbane, CA.

This new laboratory space has been established to support a pipeline of products that target donor-derived cell-free DNA (dd-cfDNA) for the surveillance of transplant recipients. The expanded facility also includes a state-of-the-art laboratory information management system containing best-in-class NGS bioinformatics and CareDx customized software modules.

Mitch Nelles, PhD, Chief Operating Officer at CareDx, commented, "I am delighted with the progress we made. This expanded CLIA laboratory is a significant step forward for us. Our teams have worked extremely hard to establish clinical-grade sequencing while at the same time designing an optimal physical space. We are now able to offer the latest genomic technologies for our growing pipeline of assays dedicated to improvement in transplant patient management. This expansion of our CLIA laboratory is an exciting milestone in our continued commitment to patient care."

About CareDx

CareDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value, non-invasive diagnostic surveillance solutions for transplant recipients. The Company has commercialized AlloMap®, a gene expression test that aids clinicians in identifying heart transplant recipients with stable graft function who have a low probability of moderate/severe acute cellular rejection. CareDx is also pursuing the development of additional products for post-transplant monitoring of other solid organs that use a variety of technologies, including next generation sequencing, to detect donor-derived cell-free DNA to monitor the health of organs after transplantation. For more information, please visit: www.CareDx.com.

Forward Looking Statements

This press release contains forward-looking statements including, but not limited to statements regarding the Company's expectations regarding future potential, development and commercial activities. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward looking statements, including CareDx's limited operating history and experience with developing new markets; risk relating to new partnerships and commercialization of those relationships, as well as other risks stated in CareDx's filings with the SEC located at www.sec.gov. CareDx disclaims any obligation to publicly update or revise any forward looking statements to reflect events that occur or circumstances that exist after the date on which they were made.

Media Contacts

Molly Martell
Senior Director, Marketing
T: +1 415-728-6307
E: [mmartell@caredx.com](mailto:mmartell@ caredx.com)

Investor Contact

Westwicke Partners, LLC
Leigh J. Salvo Principal
T: +1 415-513-1281
E: leigh.salvo@westwicke.com